241 related articles for article (PubMed ID: 36543540)
1. Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.
Loonstra FC; de Ruiter LRJ; Koel-Simmelink MJA; Schoonheim MM; Strijbis EMM; Moraal B; Barkhof F; Uitdehaag BMJ; Teunissen C; Killestein J
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36543540
[TBL] [Abstract][Full Text] [Related]
2. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
[TBL] [Abstract][Full Text] [Related]
3. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
[TBL] [Abstract][Full Text] [Related]
4. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
[TBL] [Abstract][Full Text] [Related]
5. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
6. Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
Broos JY; Loonstra FC; de Ruiter LRJ; Gouda M; Fung WH; Schoonheim MM; Heijink M; Strijbis EMM; Teunissen C; Killestein J; de Vries HE; Giera M; Uitdehaag BMJ; Kooij G
Neurology; 2023 Aug; 101(5):e533-e545. PubMed ID: 37290971
[TBL] [Abstract][Full Text] [Related]
7. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
[TBL] [Abstract][Full Text] [Related]
8. Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
Jiang X; Shen C; Teunissen CE; Wessels M; Zetterberg H; Giovannoni G; Singh CM; Caba B; Elliott C; Fisher E; de Moor C; Belachew S; Gafson AR
Mult Scler; 2023 Aug; 29(9):1070-1079. PubMed ID: 37317870
[TBL] [Abstract][Full Text] [Related]
9. The association of menopausal hormone levels with progression-related biomarkers in multiple sclerosis.
Juutinen L; Ahinko K; Hagman S; Basnyat P; Jääskeläinen O; Herukka SK; Sumelahti ML
Mult Scler Relat Disord; 2024 May; 85():105517. PubMed ID: 38442501
[TBL] [Abstract][Full Text] [Related]
10. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
[TBL] [Abstract][Full Text] [Related]
11. Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis.
Liu C; Zhou W; Sun X; Zhang X; Xiao H; Yang H; Lin H; Lu Y; Liu Z; Qiu W; Kermode AG; Yang X; Wang Y
Mult Scler Relat Disord; 2024 May; 85():105478. PubMed ID: 38457885
[TBL] [Abstract][Full Text] [Related]
12. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
[TBL] [Abstract][Full Text] [Related]
13. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Screening and Monitoring Biomarkers for Brain Metastases.
Kim SH; Gwak HS; Lee Y; Park NY; Han M; Kim Y; Kim SY; Kim HJ
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066445
[TBL] [Abstract][Full Text] [Related]
15. Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases.
Plantone D; Stufano A; Righi D; Locci S; Iavicoli I; Lovreglio P; De Stefano N
Sci Rep; 2024 Mar; 14(1):6429. PubMed ID: 38499607
[TBL] [Abstract][Full Text] [Related]
16. Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients.
Barro C; Healy BC; Saxena S; Glanz BI; Paul A; Polgar-Turcsanyi M; Guttmann CR; Bakshi R; Weiner HL; Chitnis T
Mult Scler; 2023 Feb; 29(2):206-211. PubMed ID: 36448331
[TBL] [Abstract][Full Text] [Related]
17. Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity.
Bose G; Healy BC; Saxena S; Saleh F; Glanz BI; Bakshi R; Weiner HL; Chitnis T
Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37813595
[TBL] [Abstract][Full Text] [Related]
18. Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4.
Kessler C; Ruschil C; Abdelhak A; Wilke C; Maleska A; Kuhle J; Krumbholz M; Kowarik MC; Schüle R
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362248
[TBL] [Abstract][Full Text] [Related]
19. Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort.
de Ruiter LRJ; Loonstra FC; Jelgerhuis JR; Coerver EME; Toorop AA; van Leeuwen ICE; Noteboom S; Moraal B; Strijbis EMM; Schoonheim MM; Uitdehaag BMJ
Mult Scler Relat Disord; 2023 Mar; 71():104568. PubMed ID: 36805177
[TBL] [Abstract][Full Text] [Related]
20. Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
Rosenstein I; Nordin A; Sabir H; Malmeström C; Blennow K; Axelsson M; Novakova L
J Neurol; 2024 Jul; 271(7):4412-4422. PubMed ID: 38668889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
